Anti-egfr antibodies

Abstract

The present invention encompasses EGFR specific monoclonal antibodies, or antigen-binding portions thereof. These antibodies, or antigen-binding portions thereof, have high affinity for EGFR, inhibit the activation of EGFR, and are useful for the treatment of EGFR mediated cancers.

1 . An EGFR specific monoclonal antibody, or antigen binding portion thereof, which binds EGFR with a Kd of between 0.01 pM and 10 pM. 
     
     
         2 . An EGFR specific monoclonal antibody, or antigen binding portion thereof, which binds EGFR with a Kd no greater than 10 pM. 
     
     
         3 . The antibody or antigen binding portion thereof of  claim 1 , wherein said antibody is further characterized as inhibiting EGFR activation. 
     
     
         4 . The antibody or antigen binding portion thereof of  claim 1  wherein said antibody comprises a HCDR1 comprising the amino acid sequence as shown in SEQ ID NO: 43, a HCDR2 comprising the amino acid sequence as shown in SEQ ID NO: 44, a HCDR3 comprising the amino acid sequence as shown in SEQ ID NO: 45, a LCDR1 comprising the amino acid sequence as shown in SEQ ID NO: 46, a LCDR2 comprising the amino acid sequence as shown in SEQ ID NO: 35 and a LCDR3 comprising the amino acid sequence as shown in SEQ ID NO: 47. 
     
     
         5 . (canceled) 
     
     
         6 . (canceled) 
     
     
         7 . The monoclonal antibody of  claim 4 , wherein the antibody is a humanized antibody. 
     
     
         8 . An isolated nucleic acid, comprising a polynucleotide encoding the antibody of  claim 7 . 
     
     
         9 . An expression vector comprising the nucleic acid according to  claim 8 . 
     
     
         10 . A host cell stably transfected with the expression vector of  claim 9 . 
     
     
         12 . (canceled) 
     
     
         13 . (canceled) 
     
     
         14 . A method of using the antibody of  claim 7  to treat EGFR-mediated cancer in a patient in need thereof. 
     
     
         15 . (canceled)